2020年 第6卷 第10期
《工程（英文）》 >> 2020年 第6卷 第10期 doi: 10.1016/j.eng.2020.05.017
感染新型冠状病毒的2型糖尿病患者的临床特征和结果——一项回顾性研究
a The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China
b Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China & Key Unit of Modulating Liver to Treat Hyperlipemia SATCM & Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China
c The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510120, China
d The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510120, China
e School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510006, China
# These authors contributed equally to this work.
下一篇 上一篇
摘要
据报道，糖尿病及其相关的代谢性疾病是新型冠状病毒肺炎（coronavirus disease 2019, COVID-19）患者的主要合并症。这项临床研究旨在调查有或没有合并糖尿病的COVID-19患者的临床特征、影像学和实验室检查、并发症、治疗方法以及临床结局。这项回顾性研究纳入2020年1月12日至3月25日208例经实验室确认的COVID-19的住院患者（≥45岁）。分析病历信息包括临床特征、影像学和实验室检查、并发症、治疗和临床结果。其中，96名（46.2％）患者患有2型糖尿病。在COVID-19合并2型糖尿病患者中，高血压（58.3％ vs. 31.2％）、冠心病（17.1％ vs. 8.0％）和慢性肾脏病（6.2％ vs. 0％）的共存率明显高于没有2型糖尿病的COVID-19患者。COVID-19合并2型糖尿病患者的CT胸部扫描异常频率和程度显著增加，包括毛玻璃样混浊（85.6％ vs. 64.9％, P < 0.001）和双侧斑片状阴影（76.7％ vs. 37.8％, P < 0.001）。此外，患有糖尿病的COVID-19患者的血糖水平[7.23 mmol·L‒1 (IQR: 5.80~9.29) vs. 5.46 mmol·L‒1 (IQR: 5.00~6.46)]、血液中低密度脂蛋白胆固醇（low-density lipoprotein cholesterol, LDL-C）[2.21 mmol·L‒1 (IQR: 1.67~2.76) vs. 1.75 mmol·L‒1 (IQR: 1.27~2.01)]和收缩压[130 mmHg (IQR: 120~142) vs. 122 mmHg (IQR: 110~137), P < 0.001]显著高于没有糖尿病的患者（P < 0.001）。2型糖尿病和其他代谢性疾病共存于COVID-19患者中，这可能会增加发病率并加重COVID-19的病情。血糖和脂质代谢的最佳管理是确保更好的临床结果的关键。对于患有糖尿病及其他基础和慢性代谢性疾病的COVID-19患者，应提高临床警惕性。
参考文献
[ 1 ] Coronavirus disease (COVID-2019) situation reports [Internet]. Geneva: World Health Organization; c2020 [cited 7 April 2020]. Available from: https://www. who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. 链接1
[ 2 ] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–13. 链接1
[ 3 ] Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acad Radiol 2020;27(5):603–8. 链接1
[ 4 ] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. 链接1
[ 5 ] Morbidity and mortality weekly report: novel coronavirus reports [Internet]. Atlanta: Centers for Disease Control and Prevention of US Department of Health & Human Sevices; [updated 2020 May 14; cited 14 May 2020]. Available from: https://www.cdc.gov/mmwr/Novel_Coronavirus_Reports.html. 链接1
[ 6 ] Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):2000547.
[ 7 ] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. 链接1
[ 8 ] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020;5 (7):831–40.
[ 9 ] Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020;9(2):575. 链接1
[10] Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol 2020;30:e2103. 链接1
[11] Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, VillamizarPeña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623. 链接1
[12] Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. 链接1
[13] Chinese Diabetes Society. Management suggestions for patients with diabetes and novel coronavirus pneumonia. Chin J Diabetes Mellitus 2020;12(2):73–5. Chinese.
[14] Ma W, Ran X. The management of blood glucose should be emphasized in the treatment of COVID-19. J Sichuan Univ Med Sci Ed 2020;51(2):146–50. 链接1
[15] Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and metaanalysis. 2020. medRxiv:2020.03.25.20043133.
[16] Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 edition). Chin J Pract Intern Med 2018;38: 292–44.
[17] Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020;36 (7):e3319.
[18] Means C. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy. Metabolism 2020;108:154254. 链接1
[19] Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116(10)1688–99.
[20] American Diabetes Association. Standards of medical care in diabetes—2020. Diabetes Care 2020;43(Suppl 1):S3.
[21] Yel L. Selective IgA deficiency. J Clin Immunol 2010;30(1):6–10. 链接1
[22] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):1–11.
[23] Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest 2020;43:1141–7.
[24] Guo J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. Chin J Integr Med 2017;23(6):403–9. 链接1
[25] Ye DW, Rong XL, Xu AM, Guo J. Liver-adipose tissue crosstalk: a key player in the pathogenesis of glucolipid metabolic disease. Chin J Integr Med 2017;23 (6):410–4. 链接1
[26] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med 2020;8 (5):475–81. 链接1
[27] Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75 (7):1730–41.
[28] Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013;13(9): 752–61. 链接1
[29] Alqahtani FY, Aleanizy FS, El Hadi A, Mohamed R, Alanazi MS, Mohamed N, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect 2018;147:e35. 链接1
[30] Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 2006;23(6):623–8. 链接1
[31] Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193–9. 链接1
[32] Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF diabetes atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res Clin Pract 2019;157:107840. 链接1
京公网安备 11010502051620号
